Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study

TM Morgan, HM Krumholz, RP Lifton, JA Spertus - Jama, 2007 - jamanetwork.com
ContextGiven the numerous, yet inconsistent, reports of genetic variants being associated
with acute coronary syndromes (ACS), there is a need for comprehensive validation of ACS …

Early onset gastric cancer: on the road to unraveling gastric carcinogenesis

AN Milne, R Sitarz, R Carvalho… - Current molecular …, 2007 - ingentaconnect.com
Gastric cancer is thought to result from a combination of environmental factors and the
accumulation of specific genetic alterations due to increasing genetic instability, and …

CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study

CR Lee, KE North, MS Bray, DJ Couper… - Pharmacogenetics …, 2007 - journals.lww.com
Objective The cytochromes P450 epoxygenases CYP2J2 and CYP2C8 synthesize
epoxyeicosatrienoic acids, which regulate endothelial function. We sought to determine if …

Aspirin resistance

HA Tran, SS Anand, GJ Hankey, JW Eikelboom - Thrombosis research, 2007 - Elsevier
Aspirin resistance refers to less than expected suppression of thromboxane A2 production
by aspirin and has been reported to be independently associated with an increased risk of …

Mitochondrial haplogroup N9b is protective against myocardial infarction in Japanese males

Y Nishigaki, Y Yamada, N Fuku, H Matsuo, T Segawa… - Human genetics, 2007 - Springer
Superoxide, which mitochondria mainly produce in vascular endothelial cells, plays an
important role in the pathogenesis of atherosclerosis and coronary artery disease …

Pharmacogenetics of EGFR and VEGF inhibition

J Pander, H Gelderblom, HJ Guchelaar - Drug discovery today, 2007 - Elsevier
Even though treatment of several types of solid tumours has improved in the past few years
with the introduction of the monoclonal antibodies against epidermal growth factor receptor …

Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1)

CR Lee, FG Bottone Jr, JM Krahn, L Li… - Pharmacogenetics …, 2007 - journals.lww.com
Objective Cyclooxygenase-1 (COX-1, PTGS1) catalyzes the conversion of arachidonic acid
to prostaglandin H 2, which is subsequently metabolized to various biologically active …

Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with …

Y Guo, X Zhang, W Tan, X Miao, T Sun… - Pharmacogenetics …, 2007 - journals.lww.com
Background Aberrant arachidonic acid metabolism by 12-lipoxygenase (12-LOX) and
cyclooxygenase-2 (COX-2) has been implicated in human carcinogenesis. Inherited …

COX-2 expression in atherosclerosis: the good, the bad or the ugly?

C Cuccurullo, ML Fazia, A Mezzetti… - Current medicinal …, 2007 - ingentaconnect.com
Cyclooxygenase (COX) is the rate limiting enzyme catalyzing the conversion of arachidonic
acid into prostanoids, lipid mediators critically implicated in a variety of physiological and …

Genetic determinants of C-reactive protein

JS Danik, PM Ridker - Current atherosclerosis reports, 2007 - Springer
C-reactive protein (CRP) levels are a complex phenotype with both genetic and
environmental determinants. Recent work has highlighted the impact of genetic variants …